Market Signal Briefing

Bloom Energy stock jumped after agreeing to a partnership with Brookfield Asset Management.

WASHINGTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today provided a business development update, including a supply agreement for the largest quantity of enriched silicon-28 received by the Company to date and a strategic acquisition of a radiopharmacy in the United States to complement and expand the operations of PET Labs Pharmaceuticals (Pty) Ltd (“PET Labs”), the Company's South African radiopharmaceutical operations company, dedicated to nuclear medicine and the science of radiopharmaceutical production.

The Organization of the Petroleum Exporting Countries pointed to high debt levels in key economies and tariff uncertainty as areas of concern.

If the run-up to Rachel Reeves' Budget next month has left investors wary of British banks, UBS is not joining the caution.

Its analysts have kept their “overweight” stance on the sector, arguing that cheap valuations and strong earnings momentum make the risk worth taking.

They say most traditional long-only investors are sitting tight until after the 26 November budget, unsure how the Treasury plans to plug what it calls a fiscal gap of £10–$30 billion.

Hedge funds, though, are reportedly more upbeat, spotting value in the sector’s solid returns on tangible equity, faster loan growth and improving deposit mix.

UBS thinks these trends will translate into the strongest revenue growth of any European banking market over the next couple of years.

Its top picks are the domestically focused names (Barclays PLC (LSE:BARC), NatWest Group PLC (LSE:NWG) and Paragon Banking Group PLC (LSE:PAG))alongside Standard Chartered among the internationals.

HSBC, by contrast, is rated neutral. UBS expects the coming third-quarter results season to extend the healthy momentum seen in the spring.

The key political question is whether the budget brings another tweak to the bank surcharge, which currently sits at 3%. UBS thinks a rise to around 5% is plausible, but expects any impact to be passed on to customers rather than eating into profits.

The bank doubts the government will pursue wider changes, arguing ministers still see a strong financial services sector as central to economic growth and investment.

Mortgage lending could slow into the autumn as landlords and buyers wait to see whether stamp duty or buy-to-let tax changes are in store. UBS is sceptical that higher landlord taxes would do anything to ease Britain’s housing shortage.

Earnings forecasts remain robust. The bank expects the UK lenders to grow earnings per share by between 4% and 19% in 2025, by 27% in 2026, and by 6% to 17% in 2027.

Returns on tangible equity are expected to hold at around 14.7% to 15% over the period, supporting dividend yields of roughly 8.5% to 9.2%.

On valuation, UBS notes the domestics trade at just 7.9 and 7.1 times forecast 2026 and 2027 earnings, cheaper than their continental peers.

Even the international names, at around nine times, still look good value. Policy risk may be keeping sentiment gloomy, but on these numbers the City’s big banks could yet turn out to be the contrarian’s friend.

15 out of 18 complete responders (83%) demonstrate continued complete response with median follow-up of 36 months
Reduction in surgeries compared to year prior to treatment with PAPZIMEOS was observed in 86% of patients in Year 1, 91% in Year 2, and 95% in Year 3
No new safety events observed during long-term follow-up

, /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced long-term follow-up data demonstrating durable responses to PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). These data were presented at the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF) 2025 Annual Meeting. PAPZIMEOS was granted full approval by the United States Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP.

PAPZIMEOS approval was supported by results from the pivotal study, which successfully met its primary safety and pre-specified primary efficacy endpoints. PAPZIMEOS was well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than Grade 2. 51% (18 out of 35) of study patients achieved complete response (95% CI: 34-69%), requiring no surgeries in the 12-month period after treatment with PAPZIMEOS. Results from the pivotal clinical study of PAPZIMEOS were published in The Lancet Respiratory Medicine.

Key data highlights from the AAO-HNSF presentation:

15 out of the 18 complete responders (83%) in the pivotal study demonstrated ongoing complete responses as of the September 19, 2025 data cutoff, with:

Median duration of follow-up of 36 months (range: 27-37 months);
Median duration of complete response yet to be reached; and
No new safety events observed during long-term follow-up.

Prolonged reduction in the requirement for surgical intervention to manage RRP was observed throughout long-term follow-up of evaluable study patients compared to the year prior to treatment. The percent of patients with a decrease in the number of surgeries, compared to pre-treatment was:

86% in Year 1;
91% in Year 2; and
95% in Year 3.

"The updated durability data reinforce that PAPZIMEOS is not only a medical breakthrough but a transformative therapy for the RRP community," said Helen Sabzevari, PhD, President and CEO of Precigen. "For patients and their families, sustained responses mean freedom from the relentless cycle of repeat surgeries, reduction in the risk of surgical damage, and the possibility to improve quality of life. For physicians, it provides confidence in a safe and effective therapy that addresses the root cause of disease. And for the healthcare system, durable responses translate into fewer procedures, reduced complications, and lower long-term burden of care. This is precisely the type of impact we envisioned when we set out to develop what would become the first FDA-approved therapy for adults with RRP."

About RRP
RRP is a rare, debilitating, and potentially life-threatening disease of the upper and lower respiratory tract caused by chronic HPV 6 or HPV 11 infection. RRP can lead to severe voice disturbance, compromised airways, and recurrent post-obstructive pneumonia. Although rare, RRP has the potential for transformation to malignant cancer and can be fatal. Management of RRP has primarily consisted of repeated surgeries, which do not address the underlying cause of the disease and can be associated with significant morbidity as well as significant patient and health system burden. As the number of lifetime surgeries increases, the risk for irreversible iatrogenic laryngeal injury increases with each surgery, and patients may undergo hundreds of these surgeries over their lifetimes. RRP can impact patients' work and social lives, financial stability, and mental health. Patients with RRP can experience substantial impacts to daily living with decreased quality of life and high health care utilization. Based on an internal analysis of claims data and electronic health records, there are approximately 27,000 adult RRP patients in the US.

About PAPZIMEOS™ (zopapogene imadenovec-drba), for subcutaneous injection only
PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP and the first and only approved therapy to address the root cause of RRP. PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen comprising selected regions of human papillomavirus (HPV) types 6 and 11 proteins. PAPZIMEOS is designed to generate an immune response directed against HPV 6 and HPV 11 proteins in patients with RRP. Discovered and designed in Precigen's labs using Precigen's proprietary AdenoVerse therapeutic platform, PAPZIMEOS represents a new therapeutic paradigm for RRP.

Indication and Important Safety Information

What is PAPZIMEOS?
PAPZIMEOS is a type of immunotherapy used to treat a condition called recurrent respiratory papillomatosis (RRP) in adults.

What is the most important information I should know about PAPZIMEOS?
Some people may have a reaction to the shot. Signs and symptoms may include redness, pain, swelling, itching, or warmth where the shot was given. After your first treatment, your healthcare provider will watch you for at least 30 minutes to make sure you're feeling okay.

Please contact your doctor immediately if you develop an infection, the reaction to your shot worsens, or you experience any of the below symptoms, which may indicate a systemic allergic reaction:

Difficulty breathing
Widespread rash
Facial swelling

Thrombotic events (blood clots that block your blood vessels) may occur after your PAPZIMEOS shot. Please notify your doctor immediately if you have the following symptoms:

Shortness of breath
Chest pain
Leg swelling
Persistent abdominal pain
Severe or persistent headaches
Blurred vision

What should I know before taking PAPZIMEOS?
Before taking PAPZIMEOS, tell your healthcare provider about all of your medical conditions, including:

If you are pregnant or plan to become pregnant because it is not known if PAPZIMEOS will harm the unborn baby.
If you are breastfeeding or plan to breastfeed. It is unknown if PAPZIMEOS is present in breast milk, or how it affects the breastfeeding child or milk production. Talk to your healthcare provider about the best way to feed your baby during treatment with PAPZIMEOS.

What are the most common side effects of PAPZIMEOS?
The most common side effects include:

Pain, redness, or swelling where the shot was given
Feeling tired
Chills
Fever
Muscle aches
Nausea (feeling sick)
Headache
Increased heart rate
Diarrhea
Vomiting
Sweating a lot

These are not all of the possible side effects of PAPZIMEOS. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Precigen, Inc. at 1-855-PGE-NRRP (1-855-743-6777).

Please see full Prescribing Information .

Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a biopharmaceutical company specializing in the advancement of innovative precision medicines to address difficult-to-treat diseases with high unmet patient need. Precigen is dedicated to advancing scientific breakthroughs from proof-of-concept through commercialization. With a strong commitment to innovation, Precigen is developing a robust pipeline of differentiated therapies across its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.

Trademarks
Precigen, PAPZIMEOS, AdenoVerse, and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects. Examples of forward-looking statements include, among others, information relating to the Company's business and business plans, the success of efforts to commercialize PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of recurrent respiratory papillomatosis (RRP) in adults, the Company's ability to successfully obtain foreign regulatory approvals for PAPZIMEOS, expectations about the safety and efficacy of PAPZIMEOS and the Company's other product candidates, the timing of clinical trials and their results, the Company's ability to commence clinical studies or complete ongoing clinical studies, and the ability of PAPZIMEOS to treat RRP. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

Investor Contact:
Steven M. Harasym
Tel: +1 (202) 365-2563
[email protected]

Media Contact:
Donelle M. Gregory
[email protected]

SOURCE Precigen, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (“Marex”; NASDAQ: MRX), the diversified global financial services platform, today announced that its Chief Executive Officer Ian Lowitt purchased 32,465 ordinary shares in Marex in the open market on Friday October 10, bringing his total holding to 2,615,016 ordinary shares. About Marex Marex Group plc (NASDAQ: MRX) is a diversified global financial services platform providing essential liquidity, market access and infrastructure services to clients across energy, commodities and financial markets.

, /PRNewswire/ -- Daqo New Energy Corp. (NYSE: DQ) ("Daqo New Energy" or the "Company"), a leading manufacturer of high-purity polysilicon for the global solar PV industry, today announced it plans to release its unaudited financial results for third quarter of 2025 ended September 30, 2025 before U.S. markets open on Monday, October 27, 2025.

The Company has scheduled a conference call to discuss the results at 8:00 AM U.S. Eastern Time on Monday, October 27, 2025 (8:00 PM Beijing / Hong Kong time on the same day).

The dial-in details for the earnings conference call are as follows:

Participant dial in (U.S. toll free): +1-888-346-8982

Participant international dial in: +1-412-902-4272

China mainland toll free: 4001-201203

Hong Kong toll free: 800-905945

Hong Kong local toll: +852-301-84992

Please dial in 10 minutes before the call is scheduled to begin and ask to join the Daqo New Energy Corp. call.

Webcast link:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=PBni7hsJ

A replay of the call will be available 1 hour after the conclusion of the conference call through November 3, 2025. The dial in details for the conference call replay are as follows:

U.S. toll free: +1-877-344-7529

International toll: +1-412-317-0088

Canada toll free: 855-669-9658

Replay access code: 9478610

To access the replay through an international dial-in number, please select the link below.

https://services.choruscall.com/ccforms/replay.html

Participants will be asked to provide their name and company name upon entering the call.

About Daqo New Energy Corp.

Daqo New Energy Corp. (NYSE: DQ) ("Daqo" or the "Company") is a leading manufacturer of high-purity polysilicon for the global solar PV industry. Founded in 2007, the Company manufactures and sells high-purity polysilicon to photovoltaic product manufacturers, who further process the polysilicon into ingots, wafers, cells and modules for solar power solutions. The Company has a total polysilicon nameplate capacity of 305,000 metric tons and is one of the world's lowest cost producers of high-purity polysilicon.

For more information, please visit www.dqsolar.com

SOURCE Daqo New Energy Corp.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Also from this source

October 13, 2025 07:00 ET

 | Source:

BioXcel Therapeutics

NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel’s breakthrough progress in addressing one of the most urgent unmet needs in psychiatry: the treatment of agitation associated with bipolar disorders and schizophrenia.

“It is a profound honor to ring the Nasdaq closing bell on behalf of the entire BioXcel team,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “This moment reflects not only how far we’ve come as an organization, but also our unwavering commitment to patients, families, and caregivers affected by mental illness. With the successful completion of our SERENITY At-Home pivotal trial, we are one step closer to our goal of redefining how agitation is managed and bringing IGALMI® directly to patients where they need it most: in the comfort and safety of their own homes.”

“Each milestone we achieve reinforces our belief that technology and compassion can converge to deliver meaningful change,” added Mehta. “As we celebrate this moment on the Nasdaq stage, we remain focused on our ultimate mission — to transform the standard of care in neuropsychiatry and improve lives around the world.”

The Nasdaq Closing Bell ceremony will take place at the Nasdaq MarketSite, 4 Times Square, New York, beginning at 3:45 PM ET on October 14, 2025. The ceremony can be viewed live at https://www.nasdaq.com/marketsite/bell-ringing-ceremony

About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the Company’s planned advancement of its SERENITY program; redefining how agitation is managed; bringing IGALMI® directly to patients in the at-home setting; transforming neuroscience through the strategic use of AI-driven drug discovery and human insight; reimagining existing medicines and accelerating the development of innovative therapies; transforming the standard of care in neuropsychiatry and improve lives around the world; the ringing the Nasdaq closing bell. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI® or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI®; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investors section of the Company’s website at www.bioxceltherapeutics.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contact Information

Corporate/Investors
Russo Partners
Nic Johnson
[email protected]
1.303.482.6405

Media
Russo Partners
David Schull
[email protected]
1.858.717.2310

October 13, 2025 07:00 ET

 | Source:

Forterra

Washington, D.C., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Washington, D.C., Oct. 13, 2025 — Forterra, the leader in autonomous mission systems today announced it has expanded its mission-ready autonomy solutions suite with four integrated modules, AutoDrive®, TerraLink, OASIS and Vektor. These modules are designed to transform logistics, mobility and interoperability to offer warfighters best-in-class autonomous systems solutions.

When it comes to fighting adversaries in the battlefield, precision, agility, speed and communications are all critical elements of maintaining a tactical advantage. Modern warfare runs on data, and today’s warfighters are facing more of it than any human can process fast enough to stay ahead. Each mission module within Forterra’s autonomy solutions suite can be independently integrated across a range of platforms, strengthening existing technologies. When used together, the four modules deliver a unified system that enhances situational awareness, reducing cognitive load and thereby helping Soldiers stay ahead of the fight.

AutoDrive®
AutoDrive® is an advanced autonomous driving system that enables reliable, real-time vehicle autonomy across complex, dynamic environments from battlefield operations to civilian logistics hubs. Originally designed for defense, this system-agnostic autonomy stack can be used in logistics and infrastructure applications as well, turning complex operations into coordinated, self-directed movement. It ingests and computes large amounts of data by combining advanced navigation and sensor technologies; this allows integrated vehicles to read the terrain and make decisions in real time.

TerraLink™
TerraLink is Forterra’s modular autonomous vehicle management platform, delivering robust command-and-control capabilities for seamless interoperability across diverse operational environments. It enables users and connected devices to work from the same live data picture, and it keeps critical information flowing in, even where conditions are unpredictable or bandwidth is limited.

Vektor™
Autonomy cannot exist without communications, and Vektor provides a secure, integrated communications network. Designed to integrate nearly any tactical waveform, Vektor is the secure communications hub for tactical units. It was developed to deliver high-bandwidth data flow and cross-waveform tranmissions in GPS-denied settings to ensure situational awareness when it matters most.

OASIS™
With its open interface system, OASIS standardizes hardware and software integration to allow sensors, effectors and payloads to be added and reconfigured as needed. This level of adaptability gives Forterra partners and customers the power to rapidly deploy new capabilities to maximize mission readiness.

Built with interoperability in mind, each module can be seamlessly integrated into any platform or system. Together, they create a scalable autonomy suite that allows Forterra’s customers to tailor their solutions.

“We developed these modules to operate as a cohesive autonomy system,” said Forterra CTO Joseph Putney. “Each of these modules strengthens a critical layer of the autonomy stack. Together, our customers get an end-to-end capability that can execute in real time so warfighters can focus on the mission and not the machinery.”

To learn more about these mission modules be sure to visit the Forterra booth (#6552) at AUSA 2025, or go to www.forterra.com.

Contact Info

Sanaz Tahernia
[email protected]
+1 240-631-0008

-

New advancement lays groundwork for quantum-enhanced modeling in carbon capture and molecular dynamics

COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), a leading quantum company, today announced a significant advancement in quantum chemistry simulations, demonstrating the accurate computation of atomic-level forces with the quantum-classical auxiliary-field quantum Monte Carlo (QC-AFQMC) algorithm. This demonstration – in collaboration with a top Global 1000 automotive manufacturer – proved more accurate than those derived using classical methods and marks a milestone in applying quantum computing to complex chemical systems.

Computational chemistry techniques are used to predict forces arising from the atomic interactions and can be used to determine chemical reactivity. The ability to simulate atomic forces with extreme precision is critical for modeling materials that absorb carbon more efficiently. Accurate force calculations are essential for modeling how molecules behave and react, which is foundational to everything from drug discovery to decarbonization. With results shown by IonQ’s demonstration, quantum computing’s role in solving real-world chemistry problems has made meaningful progress.

Unlike previous research which focused on isolated energy calculations, IonQ’s implementation enabled the calculation of nuclear forces at critical points where big changes occur. These forces can be fed into classical computational chemistry workflows to trace reaction pathways, improving estimated rates of change within systems, and aiding in the design of more efficient carbon capture materials.

“This research demonstrates a clear path for quantum computing to enhance chemical simulations that are foundational to decarbonization technologies,” said Niccolo de Masi, Chairman and CEO at IonQ. “Our work goes beyond academic benchmarks. It demonstrates a practical capability that can be integrated into molecular dynamics workflows used across pharmaceuticals, battery, and chemical industries.”

Building on IonQ’s prior collaborations in computational chemistry, this advancement extends IonQ’s work with the QC-AFQMC algorithm, one of the methods that IonQ believes will deliver commercial advantage in the coming years, while adding another use case that deepens the company’s expertise and expands its quantum chemistry portfolio.

About IonQ

IonQ, Inc. [NYSE: IONQ] is a leading quantum company delivering solutions to solve the world’s most complex problems. IonQ’s current generation quantum computers, IonQ Forte and IonQ Forte Enterprise, are the latest in a line of cutting-edge systems that have been helping customers and partners such as Amazon Web Services, AstraZeneca, and NVIDIA achieve 20x performance results.

The company is accelerating its technology roadmap and intends to deliver the world’s most powerful quantum computers with 2 million qubits by 2030 to accelerate innovation in drug discovery, materials science, financial modeling, logistics, cybersecurity, and defense. IonQ’s advancements in quantum networking and sensing also position the company as a leader in building the quantum internet.

The company’s innovative technology and rapid growth were recognized in Fortune Future 50, Newsweek’s 2025 Excellence Index 1000, Forbes’ 2025 Most Successful Mid-Cap Companies list, and Built In’s 2025 100 Best Midsize Places to Work in Washington DC and Seattle, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature are intended to identify forward-looking statements. These statements include those related to the IonQ’s quantum computing capabilities and plans; IonQ’s technology driving commercial quantum advantage or delivering scalable, fault-tolerant quantum computing in the future; the relevance and utility of quantum algorithms and applications run on IonQ’s quantum computers; the necessity, effectiveness, and future impacts of IonQ’s offerings available today; and the scalability, fidelity, efficiency, viability, accessibility, effectiveness, importance, reliability, performance, speed, impact, practicality, feasibility, and commercial-readiness of IonQ’s offerings. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: IonQ’s ability to implement its technical roadmap; changes in the competitive industries in which IonQ operates, including development of competing technologies; IonQ’s ability to deliver, and customers’ ability to generate, value from IonQ’s offerings; IonQ’s ability to deliver higher speed and fidelity gates with fewer errors, enhance information transfer and network accuracy, or reduce noise and errors; IonQ’s ability to sell effectively to government entities and large enterprises; changes in laws and regulations affecting IonQ’s and its suppliers’ businesses; IonQ’s ability to implement its business plans, forecasts, roadmaps and other expectations, to identify and realize partnerships and opportunities, and to engage new and existing customers; IonQ’s ability to effectively enter new markets; IonQ’s ability to deliver services and products within currently anticipated timelines; IonQ’s inability to attract and retain key personnel; IonQ’s inability to effectively integrate its acquisitions; IonQ’s customers deciding or declining to extend contracts into new phases; the inability of IonQ’s suppliers to deliver components that meet expectations timely; changes in U.S. government spending or policy that may affect IonQ’s customers; and risks associated with U.S. government sales, including availability of funding and provisions that allow the government to unilaterally terminate or modify contracts for convenience; changes in laws and regulations affecting IonQ’s patents; and IonQ’s ability to maintain or obtain patent protection for its products and technology, including with sufficient breadth to provide a competitive advantage. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent periodic financial report (10-Q or 10-K) filed by IonQ with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations. IonQ may or may not choose to practice or otherwise use the inventions described in the issued patents in the future.

More News From IonQ, Inc.

Back to Newsroom

ANN ARBOR, Mich., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company", “Kraig” or "Kraig Labs"), a world leader in spider silk technology*, is proud to announce the Company has succeeded in significantly increasing the production throughput of its recombinant spider silk production platform.

This increase is the successful result of the Company's continuous work in the selective breeding of parental strains for its production hybrid silkworms, which is the basis of its recombinant spider silk production system. Kraig's first successful hybrid, designated the BAM-1, demonstrated hybrid vigor, which increased both cocoon shell weight (a critical measure of silk output) and robustness. That hybrid was created by mating two genetically divergent parental strains. The fielding of the BAM-1 was a major improvement in spider silk production technology.

Over the past two years, Kraig Labs has used selective breeding to create more advanced parental strains with the goal of increasing hybrid vigor to further increase shell weight. One of these new advanced strains was specifically designed as a replacement for one of the original BAM-1 parental strains.

By mating the strongest of the BAM-1 parental strains with the new advanced strain, Kraig Labs has demonstrated measurable hybrid vigor (as measured by cocoon shell weight) of 22%, an increase in hybrid vigor of more than 245% compared to the BAM-1. The new advanced hybrid has been designated as BAM-1 Alpha and will be the Company's production workhorse moving forward.

"Our small team of researchers continues to outperform our competitors in spider silk R&D and commercial development. The creation of our new BAM-1 Alpha hybrid is the product of our focused vision for large-scale commercialization of spider silk and the dedication of our geneticists to that vision," said Kim Thompson, Founder and CEO of Kraig Labs. "Frankly, the 250% increase in hybrid vigor over the original BAM-1 has significantly exceeded our expectations and design parameters. The BAM-1 Alpha is producing larger cocoons and more silk, resulting in increased throughput and lower production cost. Though we do not have hard data yet on increases in robustness other than cocoon size and shell weight, our expectation is that general robustness will follow this same pattern."

Kraig Labs utilizes its proprietary genetically enhanced silkworm technology platform to produce recombinant spider silk. These silkworms spin recombinant spider silk fibers naturally within their cocoons, combining the scalability of traditional sericulture with the superior performance of spider silk proteins.

With BAM-1 Alpha now moving into commercial deployment, Kraig Labs will leverage its multi-facility production infrastructure to integrate this enhanced production hybrid into ongoing manufacturing. This advancement supports the Company's vision of delivering high-performance spider silk fibers for applications spanning performance textiles, defense, medical, and industrial markets.

This latest development underscores Kraig Labs' commitment to continuous innovation and its leadership in developing scalable bioengineered materials inspired by nature's toughest fibers.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
[email protected]

It’s not exactly a gold rush, but copper is quietly up about 27% in 2025. That’s not even close to the runup in gold or silver, but it’s still notable. The industrial metal is frequently referred to as “Dr. Copper” because the price of copper often predicts the health of the world’s economy.

That’s why copper has had volatile swings in the past 20 years. In the 2010s, copper’s fortunes were largely tied to infrastructure in China. However, in 2025, that story is being told on American soil. Support for copper prices comes from:

The AI revolution and the need for data centers and the electricity to power them

The need to upgrade the country’s existing electric grid

The ongoing demand for renewable energy solutions, including electric vehicles

That’s only a partial list, and although the focus is largely on the United States, there is a global case for copper.

But there’s also a supply issue. Chile and Peru are two of the leading sources of copper, but both countries have experienced supply disruptions. Furthermore, there aren’t enough significant new mining operations to keep up with the anticipated demand.

For investors, rising demand with supply constraints is a bullish sign that could mean the sector is at the beginning of a super cycle that could push the spot price of copper to $6 or higher for an extended period. Here are three basic materials stocks that are well-positioned for such a bull case.

Freeport-McMoRan: A Global Leader Facing Short-Term Disruption
Freeport-McMoRan Today

FCX

Freeport-McMoRan

$40.92 -2.40 (-5.53%)

As of 10/10/2025 03:59 PM Eastern

This is a fair market value price provided by Polygon.io. Learn more.

52-Week Range$27.66▼

$50.28Dividend Yield0.73%

P/E Ratio31.00

Price Target$46.56

Any discussion of copper stocks to buy must include Freeport-McMoRan Inc. NYSE: FCX. The company is one of the world’s largest publicly traded copper producers and supplies approximately 70% of all the domestically refined copper in the United States.

Although copper is its main source of mining revenue, Freeport-McMoRan also mines gold, which adds to its allure as gold demand is at record levels.

However, the company has faced significant disruption at some of its key operations in 2025 that has caused the company to scale back its full-year production estimates.

FCX stock is up just 13% in 2025, but it’s still trading about 6% below the analysts’ consensus price. But if recent upgrades accurately state the bull case, the consensus price may be far too low, which suggests that the stock could be part of a catch-up trade.

Southern Copper: Strong Gains, But a Valuation Reset May Loom
Southern Copper Today

$125.00 -5.57 (-4.27%)

As of 10/10/2025 03:59 PM Eastern

52-Week Range$74.84▼

$136.49Dividend Yield2.56%

P/E Ratio27.35

Price Target$109.88

Year-to-date growth is not a concern for Southern Copper Corporation NYSE: SCCO, one of the other large miners in this space. However, the stock is up 43% in 2025, and many analysts believe that a significant correction is overdue.

The bearish sentiment has to do with logistics more than copper fundamentals. With the current run-up, SCCO stock now trades around 29x earnings, a significant premium to its historical average of around 16x earnings.

The core issue comes down to the company’s operational footprint, which is mostly in Peru and Mexico, two countries that present significant regulatory concerns. The company’s production will be limited to these locations, which puts a ceiling on near-term growth.

The consensus price target for SCCO stock is around $109 per share. That would be a dip of around 15% from the stock’s closing price on October 9. However, an entry point in the stock would look more attractive at that price and with a lower valuation.

Global X Copper Miners ETF: A Diversified Play on the Metal Boom
Global X Copper Miners ETF Today

COPX

Global X Copper Miners ETF

$60.46 -3.52 (-5.50%)

As of 10/10/2025 04:10 PM Eastern

52-Week Range$30.77▼

$66.20Dividend Yield1.29%

Assets Under Management$3.36 billion

Many investors want exposure to mining and metals, but may not want to be stock pickers. That makes the Global X Copper Miners ETF NYSEARCA: COPX an attractive choice.

The name may be a little misleading. As of October, only about 17% of the fund’s holdings were dedicated to copper. That's likely a rotation play as 54% of the fund’s holdings are in precious metals. It also explains why the COPX fund is up more than 65% in 2025.

However, if copper follows the price of gold higher in the fall, the fund will have further to run.

In addition to its copper exposure, about 20% of the holdings are in diversified miners, such as Freeport-McMoRan and Southern Copper which are two of the fund’s top three holdings.

Should You Invest $1,000 in Global X Copper Miners ETF Right Now?Before you consider Global X Copper Miners ETF, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global X Copper Miners ETF wasn't on the list.

While Global X Copper Miners ETF currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Luxembourg – 13 October 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its third quarter 2025 results for the period ended 30 September 2025 on Thursday 20 November 2025 at 08:00 CET.

A conference call and simultaneous webcast for the investment community will be held on Thursday 20 November 2025 at 12:00 UK / 13:00 CET.

From 08:00 CET the results announcement and the presentation to be reviewed during the conference call and webcast will be available on the Subsea7 website: www.Subsea7.com

Conference call registration:

Phone:         https://register-conf.media-server.com/register/BI0e0631b7e1de4c3eaf839db3bd00a6b6
Webcast:     https://edge.media-server.com/mmc/p/8qhn7ef3/    

Please note that questions can only be submitted from a phone line. 

*******************************************************************************
Subsea7 creates sustainable value by delivering the offshore energy transition solutions the world needs.

Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62.

******************************************************************************* 
Contact for investor enquiries:
Katherine Tonks
Head of Investor Relations
Subsea 7 S.A.
Tel +44 20 8210 5568
[email protected]

www.subsea7.com

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 13 October 2025 at 13:10 CET.

SUBC 3Q25 Conference Call

Tesla (NASDAQ: TSLA) has sold over 16,000 Cybertrucks so far in 2025, averaging around 59 vehicles per day across the first three quarters, according to new figures analyzed by Finbold research. Yet despite the milestone, sales have dropped sharply from last year, highlighting waning momentum for Tesla’s most unconventional model.

While the futuristic pickup initially generated strong consumer interest following its highly anticipated rollout in late 2023, the latest figures reveal a sharp decline in sales momentum compared with last year.

In the first quarter of 2025, Tesla delivered 6,406 Cybertrucks, the strongest quarterly performance of the year so far. Sales momentum weakened significantly in the second quarter, with deliveries falling to 4,306 units, a decline of more than 50% compared with Q2 2024 and around one-third lower than Q1 2025. 

The third quarter brought a modest rebound, with 5,385 Cybertrucks sold. Even so, sales were still down 62.6% year-over-year, a steep drop from the 14,416 units delivered in Q3 2024. 

The model’s share of the EV market also slipped to 1.2%, compared with 1.5% a year earlier. Overall, Tesla has sold 16,097 Cybertrucks in the first nine months of 2025, a 38% decline from the 25,974 units recorded over the same period in 2024.

Tesla’s electric vehicle sales
Although sales have slowed, the Cybertruck remains one of the most recognizable and polarizing vehicles in the EV market. When placed in the context of Tesla’s broader electric vehicle portfolio, the Cybertruck remains a niche contributor. 

The Model Y continues to dominate sales for the company, with 265,068 units delivered year-to-date, securing more than a quarter of total EV sales in the period. Whereas, the Model 3 followed with 155,180 sales, while the Model S and Model X posted more modest numbers of 4,509 and 10,306 respectively.

The decline in Cybertruck sales highlights a mix of challenges for Tesla and the wider electric pickup market. At the same time, rising competition from Rivian, Ford, and other EV manufacturers has intensified the battle for market share in the electric truck segment. 

Broader macroeconomic conditions, including high financing costs and weaker consumer sentiment for large discretionary purchases, may also be weighing on demand.

Strategic teaming agreement leverages complementary strengths to deliver secure, flexible, and rapidly updatable solutions for Army modernization

, /PRNewswire/ -- General Dynamics Land Systems and Parry Labs today announced a strategic teaming agreement to collaborate on advancing digital integration for combat systems. The partnership reflects a shared commitment to delivering modernization solutions that keep pace with evolving Army requirements, including the ability to rapidly maintain, sustain, and integrate new technology across General Dynamics Land Systems platforms.

"Parry Labs is focused on enabling the Army to move at the speed of modern warfare," said John "JD" Parkes, CEO and Founder of Parry Labs. "Through this teaming agreement with General Dynamics Land Systems, we are bringing commercial AI infrastructure and an end-to-end software delivery environment that ensures the Army's leading ground combat systems maintain dominance through continuous software delivery."

General Dynamics Land Systems brings proven leadership in combat vehicle platforms, while Parry Labs contributes deep expertise in digital engineering, software integration, and edge computing. Together, the companies offer a complementary blend of capabilities that enable rapid, secure, and adaptable upgrades across mission systems. By leveraging open architectures and Parry's digital integration toolkit, the team will deliver continuous software upgrades, streamline integration costs, and accelerate deployment of new capabilities.

"General Dynamics Land Systems is committed to ensuring our service members have the most advanced and adaptable combat systems in the world," said Jim Pasquarette, VP, Strategic Planning of General Dynamics Land Systems. "Our partnership with Parry Labs reinforces that commitment by creating a pathway for faster, more flexible, and more resilient digital modernization across our family of systems."

The teaming agreement positions General Dynamics Land Systems and Parry Labs to pursue joint opportunities that emphasize safe, secure, and rapid software delivery to the warfighter, while advancing open system standards to ensure long-term flexibility and interoperability. The companies plan to highlight their partnership during the Association of the United States Army (AUSA) Annual Meeting in Washington, D.C. and continue aligning on future initiatives to accelerate Army modernization.

About General Dynamics Land Systems

Land Systems is a business unit of General Dynamics (NYSE: GD). General Dynamics Land Systems provides innovative design, engineering, technology, production, and full life-cycle support for land combat vehicles around the globe. The company's extensive experience, customer-first focus and seasoned supply chain network provide unmatched capabilities to the U.S. military and its allies. More information about General Dynamics Land Systems is available at www.gdls.com.

About Parry Labs

Parry Labs integrates modular software, precision hardware, and AI infrastructure to enhance data interoperability across platforms and accelerate decision-making at the edge. Parry Labs makes combat systems more connected, flexible, and ready to adapt to the realities of modern warfare.

Parry Labs integrates modular software, precision hardware, and AI infrastructure to enhance data interoperability across platforms and accelerate decision-making at the edge. Parry Labs makes combat systems more connected, flexible, and ready to adapt to the realities of modern warfare.

SOURCE Parry Labs LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers.

, /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will unveil new data from its robust antibody-drug conjugate (ADC) platform at the 2025 European Society for Medical Oncology (ESMO) Congress, taking place October 17-21, in Berlin, Germany. Data from investigational and approved ADCs across AbbVie's portfolio such as telisotuzumab adizutecan (Temab-A),1-3 ABBV-706,4,5 and Emrelis™ (telisotuzumab vedotin),6 in patients with difficult-to-treat tumor types where there is urgent need for additional treatment options,7-15 will be featured in multiple presentations.

"Despite recent progress in the treatment of advanced solid tumors, patients still face limited options and pressing unmet needs," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie. "The compelling data we are sharing at ESMO showcases how we are advancing targeted therapies across a range of solid tumors and highlights the potential of our portfolio."

Key highlights
AbbVie will present three oral presentations for Temab-A, a next-generation, investigational c-Met directed ADC with a novel topoisomerase 1 inhibitor (Top1i) payload. Phase 1 results with Temab-A both as a monotherapy and in combination across advanced, solid tumors will be presented:

Combination with bevacizumab (Bev) in Colorectal Cancer (CRC): In biomarker unselected patients with advanced CRC who have received three or more prior lines of therapy (NCT05029882), treatment with 2.4 mg/kg dose of Temab-A plus Bev (n=30) achieved an objective response rate (ORR) of 26.7% compared to an ORR of 0% with trifluridine/tipiracil with Bev (the current standard of care (SOC), n = 20).1 Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 67% and 65% of patients, respectively.1
Monotherapy in MET-Amplified Solid Tumors: Among 100 patients with advanced MET-amplified solid tumors, including non-small cell lung cancer (NSCLC) (n=29), CRC (n=22), gastroesophageal adenocarcinoma (GEA) (n=14), and 16 other tumor types (n=35) who had progressed after SOC treatment (NCT05029882), Temab-A monotherapy achieved an ORR of 46% across all dose levels and tumor types with higher responses observed in patients with NSCLC (69%) and GEA (71%).2 The most common grade ≥3 TEAEs were anemia (40%) and neutropenia (34%).2
Monotherapy in Pancreatic Ductal Adenocarcinoma (PDAC ): Among 42 biomarker unselected patients with advanced/metastatic PDAC who experienced disease progression while receiving or after completing their first-line (1L) therapy (NCT06084481), Temab-A demonstrated an ORR of 24% overall and 40% in patients who received first-line gemcitabine-nab-paclitaxel treatment.3 Grade ≥3 TEAEs occurring in ≥10% of all patients were anemia (38%) and neutropenia (21%).3

"Temab-A continues to show meaningful clinical activity across an expanding range of solid tumors and patient populations, including patients with MET-amplification and increased c-Met expression as we have seen in previously presented data," said Vivek Subbiah, M.D., Chief, Early-Phase Drug Development, Sarah Cannon Research Institute and Temab-A investigator. "These data reinforce Temab-A's potential in multiple solid tumors and thereby warrant its further clinical investigation."

AbbVie will also present new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC with a Top1i payload, in relapsed/refractory small cell lung cancer (R/R SCLC) (NCT05599984).

A post hoc analysis on data from R/R SCLC patients enrolled in the study, whose tumors had progressed after two lines of therapy (n=80), was done to compare the anti-cancer effect of ABBV-706 monotherapy vs. platinum-based SOC. All patients in this group had received the platinum-based SOC treatment as first-line therapy (1L SOC). Progression-free survival (PFS) during 1L SOC and PFS with ABBV-706 monotherapy as a subsequent line of treatment were analyzed in the same patients by paired Kaplan-Meier analysis. The findings suggest that ABBV-706 may have the potential to replace the platinum-based SOC as a first-line treatment in SCLC.4
In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Patients with 100% ctDNA clearance had significantly higher PFS and overall survival (OS) vs. patients without ctDNA clearance.5 These data highlight the potential of ctDNA as an early response marker in SCLC.5

A Phase 2 study assessing ABBV-706 in combination with atezolizumab as replacement of platinum-based chemotherapy is currently ongoing (NCT07155174) in 1L SCLC.

Details on key presentations at the ESMO 2025 Congress are available below and the full abstracts are available via the ESMO online program.

Title

Date/Time

Session

Abstract / Presentation Number

Telisotuzumab Adizutecan (ABBV-400; Temab-A) in
Patients With MET-Amplified Advanced Solid Tumors:
Results From a Phase 1 Study

Sunday,
October 19

2:45 - 4:15 PM
CEST

Oral presentation

Proffered paper
session:
Developmental
therapeutics

Room: Bremen
Auditorium - Hall
6.2

918O

Telisotuzumab Adizutecan (ABBV-400; Temab-A) in
Combination With Bevacizumab (Bev) in Patients (Pts)
With 3+ Colorectal Cancer (CRC): Dose Expansion
Results of a Phase 1 Study

Sunday,
October 19

2:45 - 4:15 PM
CEST

Mini oral session
1 : GI tumors,lower
digestive

Room:

Cologne Auditorium
- CityCube A

731MO

Phase 1 Basket Study of Telisotuzumab Adizutecan
(Temab-A), a c-Met Protein-Targeting Antibody-Drug
Conjugate (ADC): Results from Patients (Pts) With
Pancreatic Ductal Adenocarcinoma (PDAC)

Monday,
October 20

8:30 – 10:00
AM CEST

Mini oral session
2 : GI tumours,
upper digestive

Room: Bonn
Auditorium - Hall
7.1c

2214MO

Second progression-free survival (PFS2) and
subsequent treatment in patients (pts) with folate
receptor alpha (FR⍺)-positive platinum-resistant
ovarian cancer (PROC) treated with mirvetuximab
soravtansine (MIRV) vs. investigator's choice
chemotherapy (ICC): Phase 3 MIRASOL trial

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1068P

Efficacy of ABBV-706 as second-line treatment for
patients with platinum-refractory/resistant small cell
lung cancer

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

2777P

Real World Characteristics and Outcomes of Patients
with Third Line or Later Metastatic Colorectal Cancer:
Magnetic-101 Study Results

Sunday,
October 19

12:00 – 12:45
PM CEST

E-Poster

873eP

ABBV-706, a Seizure-Related Homolog Protein 6
(SEZ6)-Targeting Antibody-Drug Conjugate (ADC), in
Patients (Pts) With Relapsed/Refractory (R/R) Small
Cell Lung Cancer (SCLC): Circulating Biomarker and
Molecular Response Analyses

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

2778P

Seizure Related 6 Homolog (SEZ6) Expression
Pattern and Prognostic Impact in a Real-World Cohort
of Patients With Small Cell Lung Cancer

Saturday,
October 18

12:00 – 12:45
PM CEST

E-Poster

2796eP

Companion diagnostic assay for c-Met protein
overexpression (OE) to identify patients (pts) who may
benefit from telisotuzumab vedotin (Teliso-V)

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1951P

Treatment outcomes in patients (pts) with advanced c-
Met overexpressing (OE) EGFR wildtype (WT)
nonsquamous (NSQ) NSCLC who had telisotuzumab
vedotin (Teliso-V) dose modifications in the
LUMINOSITY trial

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1948P

Ocular surface disorders in patients with c-Met protein-
overexpressing NSCLC treated with telisotuzumab
vedotin in the LUMINOSITY study

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1950P

METRIX: International Real-World Study of c-Met
Protein Overexpression in Patients With Advanced
/Metastatic NSCLC

Saturday,
October 18

12:00 – 12:45
PM CEST

Poster

1923P

Telisotuzumab adizutecan (Temab-A) and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

Elahere™ (mirvetuximab soravtansine) and Emrelis™ (telisotuzumab vedotin) are approved medicines being investigated for additional uses. Safety and efficacy have not been established for these unapproved additional uses.

Additional information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/.

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing information for ELAHERE™ (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv)

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,Facebook, Instagram, X (formerly Twitter) and YouTube. 

About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

References:

Cecchini M, Cruz-Correa M, Han SW, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Combination With Bevacizumab (Bev) in Patients (Pts) With 3+ Colorectal Cancer (CRC): Dose Expansion Results of a Phase 1 Study. Abstract 731MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
Murciano-Goroff YR, Kuboki Y, Strickler J, et al. Telisotuzumab Adizutecan (ABBV-400; Temab-A) in Patients With MET-Amplified Advanced Solid Tumors: Results From a Phase 1 Study. Abstract 918O presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
Harding JJ, Strickler J, Henry J, et al. Phase 1 Basket Study of Telisotuzumab Adizutecan (Temab-A), a c-Met Protein-Targeting Antibody-Drug Conjugate (ADC): Results from Patients (Pts) With Pancreatic Ductal Adenocarcinoma (PDAC). Abstract 2214MO presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
Bar J, Dowlati A, Byers LA, et al. Efficacy of ABBV-706 as second-line treatment for patients with platinum-refractory/resistant small cell lung cancer. Abstract 2777P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
Wang S, Wang L, Luo A, et al. ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with relapsed/refractory (R/R) small cell lung cancer (SCLC): Circulating biomarker and molecular response analyses. Abstract 2778P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
Mansfield AS, Goldman J, Lee SH, et al. Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial. Abstract 1948P presented at the European Society for Medical Oncology Congress, 2025. Berlin, Germany.
Cassim S, Chepulis L, Keenan R. et al. Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review. BMC Cancer. 2019; 19, 25. doi:10.1186/s12885-018-5169-9
Shalata W, Naamneh R, Najjar W, et al. Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. Med Sci. 2025; 13(3):142. doi:10.3390/medsci13030142
Daamen LA, Molenaar IQ, and Groot VP. Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence. J Clin Med. 2023; 12(23):7485. doi:10.3390/jcm12237485
Cereda V and D'Andrea MR. Pancreatic cancer: failures and hopes—a review of new promising treatment approaches. Explor Target Antitumor Ther. 2025;6:1002299. doi: 10.37349/etat.2025.1002299
Deboever N, Jones CM, Yamashita K, et al. Advances in diagnosis and management of cancer of the esophagus. BMJ. 2024; 385 :e074962 doi:10.1136/bmj-2023-074962
Huang J. Overcoming Therapeutic Barriers in Esophageal Cancer Management. J Cancer Clin Trials. 2025;10,289. doi:10.37421/2577-0535.2025.9.289.
Nishimuni M, Claro LCL, and Braghiroli MFM. Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies. Surg Exp Pathol. 2024;7,19. doi.10.1186/s42047-024-00162-4
Li H, Shen M and Wang S. Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol. 2024; 4:1327055. doi:10.3389/fonc.2024.1327055
Pathak PS, Chan G, Deming DA, et al.State-of-the-art management of colorectal cancer: Treatment advances and innovation. Am Soc Clin Oncol Educ Book, 2024; 44(3), p.e438466. doi:10.1200/EDBK_438466 

SOURCE AbbVie

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

A logo is pictured on Swiss private bank Julius Baer building in Geneva, Switzerland, November 21, 2024. REUTERS/Denis Balibouse Purchase Licensing Rights, opens new tab

SummaryCompaniesBank's claim for 48 million euros exceeds 2023 profit in GermanyNew CEO aims to reduce risk, focus on wealth managementZURICH, Oct 13 (Reuters) - Swiss private bank Julius Baer is facing significant credit losses after financing real estate projects linked to Germany's now-insolvent Degag Group, the Handelsblatt newspaper reported on Monday.
The bank has filed claims for 48 million euros ($55.74 million), which exceeds its 2023 profit in Germany, the paper said, citing a preliminary report to the insolvency administrator.

The matter is a blow for Julius Baer, which last year reported losses of 586 million Swiss francs on loans to collapsed property company Signa.

Sign up here.

"Julius Baer granted a private group of companies mortgage loans totalling a higher double-digit CHF million amount to finance residential properties in Germany," Julius Baer said in a statement to Reuters.

"Some of the borrowers in this group are now facing financial difficulties."

NEW CEO VOWS TO REDUCE BANK'S RISK PROFILEJulius Baer ousted its Chief Executive Philipp Rickenbacher last year in the wake of the Signa losses, with new CEO Stefan Bollinger pledging to reduce the bank's risk profile by focussing more on wealth management.

The report said Julius Baer was the most important bank lender to Degag, once a key player in Germany's residential property market and now at the centre of a financial scandal.

The group is reportedly indebted by up to 1.1 billion euros, with thousands of private investors facing the prospect of total losses.

Prosecutors in Hanover have launched investigations into several former executives, the newspaper said.

Julius Baer said it had announced an increase in loan loss allowances of 130 million Swiss francs ($161.87 million) on May 20.

"These allowances were related to clients in Switzerland and other European countries and across certain selected positions in the mortgage book and the remaining private debt loan book, which Julius Baer has significantly reduced since 2024," the bank said.

($1 = 0.8612 euros)

($1 = 0.8031 Swiss francs)

Reporting by John Revill; Editing by Bernadette Baum

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Shares in IP Group PLC (LSE:IPO) rose 9% on Monday after investors welcomed the potential for future royalty income from Metsera, a biotech company that Pfizer has agreed to acquire for up to $7.3 billion.

The agreement, announced in September, includes $4.9 billion in upfront cash and gives Pfizer control of Metsera’s portfolio of next-generation obesity treatments.

The most advanced candidate, MET-097i, is designed to be injected once a month rather than weekly, a potential advantage over current market leaders such as Novo Nordisk and Eli Lilly.

IP Group, the London-listed investor in breakthrough science ventures, retains financial exposure to several of Metsera’s obesity drug programmes through its former portfolio company Zihipp, which was acquired by Metsera in 2023.

The group is entitled to milestone payments and a small percentage of future sales if any of the compounds reach the market, with proceeds shared equally with Imperial College London.

Chief executive Greg Smith said the company was encouraged by Metsera’s latest phase IIb results and plans to start phase III trials next year. He added that Metsera’s therapies could “ease pressure on healthcare systems with fewer injections and better tolerability.”

The update reinforced IP Group’s position as a key backer of university spin-outs in fast-growing areas such as obesity and metabolic health.

The shares rose 5p to 58.10p.

This fast-casual salad maker has struggled to stay fresh since its IPO.

Sweetgreen (SG -4.92%), a fast-casual restaurant specializing in salads and grain bowls, attracted a lot of attention when it went public on Nov. 18, 2021. Its stock surged from its IPO price of $28 to $52 on its opening trade, and it closed at its record high of $53 a day later.

At the time, the bulls were impressed by Sweetgreen's strong same-store sales growth and ambitious expansion plans, and it was frequently called the "next Chipotle (CMG -2.53%)." The buying frenzy in growth stocks further amplified its gains and inflated its valuations.

But today, Sweetgreen's stock trades at about $8. Its valuations wilted as its same-store sales growth cooled off, inflation boosted its labor and commodity costs, and it faced tougher competitors. Should investors buy the dip and expect a recovery over the next 12 months?

Image source: Getty Images.

What happened to Sweetgreen after its IPO?
Sweetgreen carved out its niche by selling a broader range of salads and healthier foods than other fast-casual chains. At the time of its IPO, it was serving 1.35 million customers across 130 locations in 13 U.S. states. More than two-thirds of its sales were coming from digital channels. Like Chipotle, it owns and operates all of its stores instead of franchising them. That business model is more capital-intensive, but it gives the company a tighter grip on its brand and operations.

When Sweetgreen went public, its same-store sales were surging, it was opening dozens of new stores each year, and its average unit volume (AUV) -- or the average annual revenue at its stores open for at least 12 months -- was climbing by the double digits. Its high ratio of digital orders also put it ahead of other restaurants, which were scrambling to upgrade their apps.

But over the following years, its same-store sales growth dropped to the single digits. Its new store openings slowed down, its AUV flatlined, and its ratio of digital orders declined. On the bright side, its restaurant-level profit margins still expanded as its growth cooled off.

Metric

2021

2022

2023

2024

Total Revenue Growth

54%

38%

24%

16%

New Store Openings

31

36

35

25

Same-Store Sales Growth

25%*

13%

4%

6%

AUV Growth

20%*

12%

0%

0%

Total Digital Revenue Percentage

67%

62%

59%

56%

Restaurant-Level Profit Margin

12%

15%

17%

20%

Data source: Sweetgreen. *Adjusted for temporary COVID-19 closures in 2020.

Why did Sweetgreen's growth cool off?
Sweetgreen's initial growth was driven by its popularity among office workers in dense urban areas. After the pandemic's height, many of those workers pivoted toward remote work and visited its stores less frequently. It tried to offset that slowdown by expanding into suburbs and smaller cities, but its brand wasn't well-known, and it struggled to grow its sales.

As Sweetgreen's top-line growth decelerated, rising labor and commodity costs -- and a higher mix of lower-margin deliveries -- squeezed its restaurant-level profit margins. However, it offset that pressure by raising its prices and automating its stores with its "Infinite Kitchen" dispensers.

It also directly sourced more of its ingredients instead of going through intermediaries, and it improved the efficiency of its mobile app -- even as its total ratio of digital orders declined. (As it lapped the pandemic, more people returned to its stores, and it expanded into the suburbs, which favored dine-in visits.) Those improvements boosted its restaurant-level profit margins, and its adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) turned positive in 2024.

Will Sweetgreen's business keep growing?
For 2025, Sweetgreen expects its total revenue to rise 3% to 6%. However, it expects that growth to be entirely driven by "at least" 40 new restaurant openings (with 20 Infinite Kitchen locations) instead of rising same-store sales and AUV at its existing locations.

For the full year, it expects its same-store sales to decline 4% to 6%, its restaurant-level profit margin to dip to 17.5%, and its adjusted EBITDA to drop 20% to 47%. That grim outlook suggests it could fall into the trap of opening new stores to grow its near-term revenue. If those stores don't grow after the first year, they'll continue to reduce its same-store sales. The company attributed that slowdown to macro and competitive headwinds, a difficult comparison to the launch of its popular steak menu last year, and the replacement of its Sweetpath subscriptions with its new SG Rewards loyalty program.

Should you expect Sweetgreen's stock to recover?
With an enterprise value of $803.5 million, Sweetgreen still isn't cheap at 73 times this year's adjusted EBITDA. Chipotle, which anticipates roughly flat same-store sales growth this year as it opens 315 to 345 new locations, trades at just 22 times this year's adjusted EBITDA.

For now, I wouldn't touch Sweetgreen's stock unless it proves its newly opened stores can grow their same-store sales and AUV. If not, the company will get trapped in a nasty cycle of closing its underperforming stores and cutting costs to resize its business -- and its stock could sink even lower before it's considered a bargain.

Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chipotle Mexican Grill. The Motley Fool recommends Sweetgreen and recommends the following options: short December 2025 $45 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy.

Daily Light Crude Oil Futures
Any upside continuation faces stiff resistance, with the 50-day moving average at $62.77, a swing top at $62.92, and the 200-day moving average at $62.98. Of note, the 50-day has crossed below the 200-day, forming a bearish “death cross” that signals long-term weakness. Unless bulls can overcome this cluster decisively, rallies are likely to be viewed as selling opportunities.

On the downside, a failure to hold $58.22 would signal renewed selling pressure, potentially exposing the next major support at $55.74.

U.S.-China Trade Tensions Keep Traders on Edge
Oil’s rebound is partially driven by renewed investor focus on a potential meeting between U.S. President Donald Trump and China’s Xi Jinping. The meeting, tentatively slated for later this month on the sidelines of the APEC summit in South Korea, could determine whether the current tariff standoff escalates or finds relief.

Last week’s oil selloff followed an expansion of Chinese rare earth export controls and Trump’s announcement of 100% tariffs on certain Chinese goods. Market participants remain highly sensitive to any signs of resolution or further deterioration in trade talks, which significantly impact global demand sentiment for crude.

China’s Crude Imports Provide Limited Demand Support
On the demand front, China’s crude oil imports rose 3.9% year-over-year in September to 11.5 million barrels per day, according to customs data. While the increase is notable, it has done little to offset broader demand concerns tied to trade uncertainty and regional conflict resolution in the Middle East.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Additionally, the FDA has accepted BeOne's request for partici.

-

Strategic Acquisitions Expand Sealing Technologies Capabilities in Critical and Growing Areas

AlpHa Measurement Solutions Extends Core Technologies with Leading-Edge Liquid Sensing and Instrumentation Solutions for Compositional Analysis

Overlook Industries Adds to Enpro’s Critical Components Offerings in the Single-Use Biopharma Market

CHARLOTTE, N.C.--(BUSINESS WIRE)--Enpro Inc. (NYSE: NPO), an industrial technology company, today announced that it has entered into separate, definitive agreements to acquire two strategic assets in key growth areas within its Sealing Technologies segment, AlpHa Measurement Solutions (“AlpHa”) and Overlook Industries (“Overlook”), for an aggregate of approximately $280 million in cash.

“The AlpHa and Overlook acquisitions will advance our Enpro 3.0 strategy by extending our critical capabilities in key growth nodes, positioning Enpro for enhanced profitable growth, while encouraging the pursuit of personal and professional development for all colleagues,” said Eric Vaillancourt, Enpro’s President and Chief Executive Officer. “AlpHa will build on our recent acquisition of AMI to expand our offerings in Compositional Analysis while Overlook will strengthen our capabilities within the biopharma production value chain. We look forward to welcoming the impressive AlpHa and Overlook teams to the Enpro family as we capitalize on our combined strengths to accelerate future enterprise growth and value creation for our stakeholders.”

AlpHa is a Houston, Texas-based leading provider of liquid analytical sensing technologies and instrumentation for the measurement of key parameters for liquid processes. The company serves customers across a diverse set of end-markets, including industrial process control, water & wastewater, laboratory, and environmental monitoring.

AlpHa’s liquid analytical sensing and instrumentation solutions will broaden Enpro’s position in Compositional Analysis, a growing area within the Test & Measurement industry. The addition of AlpHa’s liquid analytics capabilities will expand Enpro’s existing gas stream applications acquired with AMI, offering customers a more complete suite of sensing and instrumentation solutions that ensure safety, consistency, and quality for a wide range of critical processes.

Overlook Industries, headquartered in Easthampton, Massachusetts, specializes in the design and fabrication of single-use technologies and other critical componentry for biopharmaceutical production processes. The acquisition of Overlook expands Enpro’s biopharmaceutical capabilities in liquid dose biologics, where more stringent aseptic processing is essential to contamination prevention.

Combined with Garlock Hygienic Technologies (GHT), Overlook’s technologies enhance Enpro’s solutions across the value chain of biopharma production. These strengthened capabilities provide Enpro more customer intimacy and technology expertise to better meet the industry’s growing need for tailored, single-use consumables as the production and use of biologics and cell and gene therapies accelerate.

Transaction Details

Following the completion of both transactions, AlpHa and Overlook will be included in Enpro’s Sealing Technologies segment, adding to the segment’s portfolio of products and solutions that safeguard critical environments. The combined entities are expected to show revenue growth rates higher than the Sealing Technologies segment average as well as initially contribute, on an annualized basis, more than $60 million in revenue and $17-$18 million in adjusted segment EBITDA. Enpro also expects the additions of AlpHa and Overlook to be accretive to total company profitability.

The acquisition of Overlook closed on October 8, 2025. The acquisition of AlpHa is expected to close in November 2025, subject to customary closing conditions, including regulatory approvals.

Enpro intends to provide further information with respect to the transactions in its upcoming conference call accompanying its announcement of results of operations for the three and nine months ended September 30, 2025.

About Enpro

Enpro is a leading industrial technology company focused on critical applications across many end-markets, including semiconductor, industrial process, commercial vehicle, sustainable power generation, aerospace, food and pharma, photonics, and life sciences. Headquartered in Charlotte, North Carolina, Enpro is listed on the New York Stock Exchange under the symbol “NPO”. For more information about Enpro, visit the company’s website at http://www.enpro.com.

Forward-Looking Statements

Statements in this press release that express a belief, expectation, or intention, as well as those that are not historical fact, are forward-looking statements under the Private Securities Litigation Reform Act of 1995. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: the ultimate outcome, benefits and synergies of acquisitions of Overlook and AlpHa and future financial performance, including revenues, cash flows, operating expenses and profitability, involve risks and uncertainties, and are subject to change based on various important factors, including the timing of and any potential delay in consummating the proposed acquisition of AlpHa, the risk that the conditions to closing of the acquisition of AlpHa (including the necessary regulatory approvals) may not be satisfied in the anticipated timeframe or at all and that such transaction may not close; the risk that regulatory approvals required for the acquisition of AlpHa is obtained subject to conditions that are not anticipated; the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement with respect to the acquisition of AlpHa; the possibility of unexpected costs, liabilities or delays in connection with the acquisition of AlpHa; risks that the acquisitions disrupt current plans and operations of Enpro; the risk that the disruption from the transactions may make it more difficult to maintain business and operational relationships, including retaining and hiring key personnel and maintaining relationships with Overlook’s and AlpHa’s respective vendors and others with whom they do business; risks and uncertainties with respect to Enpro’s ability to recognize the anticipated benefits of each transaction; the outcome of any legal proceedings that may arise with respect to the transactions; and the impact of changes in relevant national and regional economies. Enpro’s filings with the Securities and Exchange Commission, including its most recent Form 10‑K and Form 10‑Q, describe other risks and uncertainties.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Enpro does not undertake to update any forward-looking statements made in this press release to reflect any change in management’s expectations or any change in the assumptions or circumstances on which such statements are based.

More News From Enpro Inc.

Back to Newsroom

Jacksonville, Florida, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Everything Blockchain Inc. (OTC: EBZT), a publicly traded company developing AI-driven trading infrastructure for digital assets, today commented on the historic $19 billion crypto liquidation and outlined its vision for the automation of less than twenty-four hours, with 1.6 million traders liquidated. Bitcoin fell over $20,000 intraday, wiping out nearly $380 billion in market value, a single-day swing larger than almost every public company on Earth.

In a move that stunned analysts, a whale on HyperLiquid placed massive short positions in Bitcoin and Ethereum one minute before the Trump administration announced a 100 percent tariff increase on Chinese imports. The final short was executed at 20:49 GMT, with the announcement hitting at 20:50 GMT. Within minutes, the whale closed ninety percent of the BTC short and fully exited the ETH short, capturing an estimated $190 to $200 million profit in a single day.

To many observers, the timing looked like insider trading on a global scale. To professionals who study market structure, it was the predictable result of a system built on overleverage, thin liquidity, and emotion.

Everything Blockchain Read the Data Before the Rest of the Market Saw the Risk

Over the summer, Everything Blockchain Inc. (OTC: EBZT) identified mounting structural risk across the digital asset market.
By early October, aggregate altcoin open interest had surged from approximately 21 billion dollars to more than 38 billion dollars, a 90 percent increase, while total altcoin market capitalization rose only from 825 billion to 1.16 trillion dollars, a 25% increase.

The data revealed a growing disconnect between leverage and real market value. Recognizing this imbalance, Chief Investment Officer Gleb Zemsky advised that the company’s planned Digital Asset Treasury model, a strategy based on directional exposure, would be too vulnerable in a leverage-driven environment.

The team made a decisive shift toward a new principle: the future of finance is the automation of money.

Everything Blockchain Is Teaching Money How to Think

Everything Blockchain began developing AI-assisted systems designed to identify the safest and most consistent yield opportunities on-chain through intelligence and automation. The company’s approach combines quantitative modeling, live blockchain analytics, and adaptive execution to target the most reliable risk-adjusted returns across stablecoin yield pools, liquidity spreads, and delta neutral vaults.

“Artificial intelligence is not replacing traders,” said Chief Investment Officer Gleb Zemsky. “It is extending their reach. Our technology allows human expertise to work hand in hand with automation, creating strategies that think faster, adapt faster, and perform with discipline.”

During this recent liquidation event, the same category of strategies that the company develops internally produced strong positive returns, exceeding 40% annualized, while the broader market collapsed.

Clovermint: The Intelligence Engine for Digital Yield

Everything Blockchain is developing Clovermint, an AI-powered trading and yield infrastructure built to help capital think, react, and perform with precision. Clovermint transforms live blockchain data into actionable insights. Its AI engine scans millions of on-chain signals to identify high-confidence opportunities in stablecoin yield pools, liquidity spreads, and delta neutral strategies that generate returns independent of price direction.

Built for both institutions and sophisticated traders, Clovermint combines human expertise with automation to deliver institutional-grade performance through a simple, transparent platform. The system enhances decision-making, automation, and execution, bridging artificial intelligence, blockchain analytics, and regulated public-market access. The result is an intelligent layer that allows capital to move with purpose, safely, efficiently, and autonomously.

Everything Blockchain’s Institutional Advisory Model

While Clovermint advances toward launch, Everything Blockchain is already applying its expertise through institutional advisory services. The company structures custom delta-neutral and stable yield solutions for institutions, family offices, and high-net-worth investors who want exposure to digital markets without taking price risk.

Proceeds from these advisory engagements will strengthen the company’s balance sheet and, as management has indicated, may be used in future stock buyback initiatives to enhance shareholder value.

About Everything Blockchain Inc.

Everything Blockchain Inc. (OTC: EBZT) is a publicly traded company developing the intelligence layer of money. The company builds AI-driven trading infrastructure that analyzes blockchain data, identifies high-quality yield opportunities, and powers delta-neutral strategies for institutional and retail participants. Its flagship platform, Clovermint, will bring automated, risk-managed digital income generation to a global audience.

For more information, visit www.everythingblockchain.io

Media Contact:
Investor Relations
Everything Blockchain Inc.
Email: [email protected]
Website: www.everythingblockchain.io

Safe Harbor and Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than historical facts are forward-looking statements, including, without limitation, statements regarding the development, performance, or expected results of products, models, or strategies described herein; the company’s future business plans, objectives, or prospects; and any anticipated financial, operational, or market outcomes.

Forward-looking statements are based on current expectations, estimates, and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, changes in market conditions, volatility in digital-asset prices, regulatory developments, technology performance, the availability of financing, and other factors described in the company’s filings with the U.S. Securities and Exchange Commission or OTC Markets disclosures.

Any references in this release to model results, backtested data, or theoretical performance (including any percentages or annualized returns) are illustrative only, are not based on actual trading, and should not be regarded as indicative of future performance or results. Past or modeled performance does not guarantee future outcomes, and all investing involves risk, including possible loss of principal.

Everything Blockchain Inc. undertakes no obligation to update, revise, or publicly release the results of any revisions to these forward-looking statements or performance examples to reflect future events, circumstances, or actual results except as required by law.

WASHINGTON--(BUSINESS WIRE)--Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, will introduce its Family of Multi-Mission Autonomous Vehicles (FMAV) at the Association of the United States Army (AUSA) Annual Meeting & Exposition, October 13–15, 2025, in Hall B – Booth 1625.

As the U.S. Army accelerates its transformation, Oshkosh is demonstrating how the FMAV platforms directly support modernization priorities for long-range precision fires, resilient formations, and scalable autonomy to deliver ready-now, production-based solutions that reduce risk and increase capabilities to Soldiers in contested environments.

At AUSA, Oshkosh will showcase three production-ready variants from its FMAV portfolio:

Extreme Multi-Mission Autonomous Vehicle (X-MAV): The Oshkosh X-MAV is a purpose-built, autonomous-capable launcher solution that is engineered to support the future of long-range munitions. With a robust chassis for the heaviest payloads, proven off-road mobility, and integrated onboard vehicle power, it’s the ideal foundation to support the Common Autonomous Multi-Domain Launcher Heavy (CAML-H) program for multi-domain missions and formations. The X-MAV will be displayed for the first time with four Tomahawk Land Attack Missiles.

Medium Multi-Mission Autonomous Vehicle (M-MAV): Derived from the Oshkosh FMTV A2, the M-MAV delivers an integrated, forward-looking solution to the U.S. Army’s most pressing challenges. Purpose-built for optionally manned or fully autonomous launcher operations, M-MAV delivers advanced navigation, remote operation, and automated resupply capabilities to increase survivability, reduce crew burden, and enable dispersed, resilient fires formations. The M-MAV will be equipped with the Multiple Launch Rocket System (MLRS) Family of Munitions (MFOM).

Light Multi-Mission Autonomous Vehicle (L-MAV): Evolved from the U.S. Marine Corps ROGUE-Fires, the L-MAV is a proven, production-ready autonomous carrier. Its modular design allows rapid configuration for missions such as counter-unmanned aerial systems (C-UAS), electronic warfare, or resupply, enabling immediate operational readiness across formations. The L-MAV will showcase the AeroVironment Switchblade 600 Loitering Munition and Titan C-UAS.

“The Army has been clear on the need for autonomous, payload-agnostic platforms that are ready now,” said Pat Williams, Chief Programs Officer at Oshkosh Defense. “The Oshkosh Family of Multi-Mission Autonomous Vehicles are engineered on proven tactical vehicles, with scalable autonomy and payload versatility to deliver what the Army needs today with the flexibility to adapt as the battlefield evolves.”

Oshkosh Defense leadership will be available to discuss the company’s entire portfolio of vehicles, mobility systems, and next-generation technologies at AUSA 2025 in booth #1625.

About Oshkosh Defense

Oshkosh Defense is a global leader in the design, production and sustainment of best-in-class military vehicles, technology solutions and mobility systems. Oshkosh develops and applies emerging technologies that advance safety and mission success. Setting the industry standard for sustaining fleet readiness, Oshkosh ensures every solution is supported worldwide throughout its entire life cycle.

Oshkosh Defense, LLC is an Oshkosh Corporation business [NYSE: OSK]. Learn more about Oshkosh Defense at oshkoshdefense.com/.

About Oshkosh Corporation

At Oshkosh (NYSE: OSK), we make innovative, mission-critical equipment to help everyday heroes advance communities around the world. Headquartered in Wisconsin, Oshkosh Corporation employs over 18,000 team members worldwide, all united behind a common purpose: to make a difference in people’s lives. Oshkosh products can be found in more than 150 countries under the brands of JLG®, Pierce®, MAXIMETAL, Oshkosh® S-Series™, Oshkosh® Defense, McNeilus®, IMT®, Jerr-Dan®, Frontline™ Communications, Oshkosh® Airport Products, Oshkosh AeroTech™ and Pratt Miller. For more information, visit oshkoshcorp.com.

®, ™ All brand names referred to in this news release are trademarks of Oshkosh Corporation or its subsidiary companies.

Forward Looking Statements

This news release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including, without limitation, statements regarding the Company’s future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations, are forward-looking statements. When used in this news release, words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project” or “plan” or the negative thereof or variations thereon or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions, and other factors, some of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include risks related to the Company’s ability to successfully execute on its strategic road map and meet its long-term financial goals. Additional information concerning these and other factors is contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this news release. The Company assumes no obligation, and disclaims any obligation, to update information contained in this news release. Investors should be aware that the Company may not update such information until the Company’s next quarterly earnings conference call, if at all.

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain

Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain

Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes

BROOMFIELD, Colo., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced participation in the International Society of Pain and Neuroscience (ISPN) Annual Meeting held last week in London.

Key Highlights:

Event: International Society of Pain and Neuroscience (ISPN) Annual Meeting — London, UKSession Focus: Use and efficacy of MR Spectroscopy in identifying discogenic pain biomarkersCompany Mission: Establish Nociscan® as the gold standard in identifying sources of chronic low back painGlobal Relevance: Over 266 million people worldwide suffer from chronic low back pain Aclarion’s Nociscan® solution is the first evidence-supported SaaS platform to noninvasively help physicians differentiate between painful and non-painful discs in the lumbar spine. Nociscan converts MR spectroscopy signals into objective biomarkers demonstrated to be associated with disc pain. This provides actionable information that enables physicians to develop more personalized treatment plans for patients.

“We are honored to be consistently included in the esteemed academic society meetings, such as ISPN, throughout the spine surgery and pain management ecosystem. This is a testament not only to the innovation of our team today, but to the vision and determination that have guided Aclarion from the very beginning,” said Brent Ness, CEO of Aclarion. “Mr. John Sutcliffe and Dr. Doug Beall represent the forefront of the neurosurgery and interventional radiology community, and we thank them for their moderation of this important discussion.”  

“The engaging panel discussion on MR spectroscopy and Nociscan, along with other essential diagnostic modalities for back pain, emphasized that a critical component for diagnosing the most common cause of back pain is the chemistry of the disc,” commented Dr. Beall. “We are very optimistic about the future of MR spectroscopy in diagnosing painful discogenic back pain.”

“The ISPN leadership’s inclusivity of orthopedic and neurosurgeons in the discussions provided an expanded, compelling perspective. We have employed a multidisciplinary spine care approach for over 30 years at the London Spine Clinic, allowing us to pioneer the use of innovative solutions to enhance treatment for our patients,” added John Sutcliffe, co-moderator of the session. “I was honored to co-moderate the important discussion and to share the UK experience with this international audience. We are proud to be the first clinic in the world with the approval from multiple private medical insurers for this study, making it available to an increasing number of appropriate patients.”

To find a Nociscan center, view our site map here.

For more information on Nociscan, please email: [email protected]

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith
PCG Advisory, Inc.
[email protected]

Media Contacts:

Jessica Starman
[email protected]